Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human Papillomavirus DNA (HPV DNA) refers to the genetic material of HPV, a non-enveloped virus. Its ~8 kb circular double-stranded DNA encodes viral replication and assembly machinery. HPV DNA's clinical relevance lies in its association with various cancers, primarily cervical cancer, and its use as a target for diagnostic tests and prophylactic vaccines. Persistent infection, especially with high-risk types like HPV 16 and 18, can lead to cellular transformation and malignancy. The HPV DNA genome contains early genes (E1-E7) that regulate viral replication and cell cycle, and late genes (L1 and L2) encoding capsid proteins. Detection of HPV DNA through PCR or hybridization is a common diagnostic method. Vaccines target L1 capsid protein, inducing neutralizing antibodies.
Vaccines stimulate antibody production against HPV capsid proteins, preventing infection. Antivirals (experimental) may target viral replication enzymes.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human Papillomavirus DNA (HPV DNA).